About defibrotide
Antithrombotic and endothelial protective agent
Used for
- Treats severe hepatic veno-occlusive disease after stem-cell transplantation.
Usual adult dose
6.25 mg/kg intravenously every six hours; treatment usually lasts at least 21 days.
Usual dose in children
6.25 mg/kg intravenously every six hours; treatment usually lasts at least 21 days.
Common side effects
- Bleeding
- Low blood pressure
- Nausea
- Vomiting
Important warnings
- Can cause serious bleeding; avoid with active bleeding or medicines that increase bleeding.
- Stop before invasive procedures when clinically appropriate.
- Avoid medicines that affect blood clotting unless carefully assessed.
- Use only under specialist supervision.
Pregnancy
Limited information; potential fetal harm is uncertain. Use during pregnancy only if clearly necessary.
Breastfeeding
It is unknown whether defibrotide passes into breast milk; breastfeeding is generally avoided during treatment.
Interactions
- Anticoagulants and antiplatelet medicines may increase bleeding risk.
- Thrombolytic medicines may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.